Celularity (CELU) announced a strategic partnership with DefEYE, a newly established ophthalmic product and technology company. Celularity has executed an exclusive license & pricing arrangement with DefEYE on the backend of Celularity’s in-kind investment in DefEYE’s $12MM Series Seed Preferred Equity funding round. “The partnership reflects a strategic opportunity to align for both companies and signals the start of a promising new chapter for regenerative therapies in eye care,” said Robert Hariri, M.D., Ph.D., Celularity’s Chairman and CEO
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELU:
- Celularity Secures $2 Million in Private Placement
- Celularity announces publication of Phase 2 study on PDA-002
- Celularity Positioned for Growth Amid Industry Disruption and Strategic Financial Restructuring
- Celularity reports Q1 EPS (84c) vs ($1.03) last year
- Celularity regains compliance with Nasdaq listing rule